[Photodynamic therapy for subretinal neovascular membranes. Communication 1. Results of treatment for age-related macular degeneration].
The purpose of the study was to assess the results of photodynamic therapy (PDT) for subretinal neovascular membranes (SNM) in age-related macular degeneration (ARMD), by using the Russian drug Photosens. According to the treatment performed, all the patients were divided into 2 groups: 1) 18 patients with the neovascular form of ARMD who received a course of PDT; 2) 14 patients with the same form who had drug therapy. Photosens (aluminum phthalocyanine) was intravenously injected in a dose of 0.05 mg/kg. The irradiation conditions were as follows: a session was carried out, using a laser at a wavelength of 675 nm, in an exposure light dose of 120 J/cm2. The number of sessions ranged from 3 to 5 a week, depending on the clinical picture of SNM. The total light dose was not greater than 500 J/ cm2. PDT showed a higher efficiency, as compared to drug therapy. PDT using Photosens increases and stabilizes visual acuity in 50% of cases, improves retinal functional activity (an increase in the mean value of a b-wave amplitude), and causes positive changes in the morphometric values of the mean neuroepithelial thickness above SNM and in the foveola.
Avetisov
S E
SE
Budzinskaia
M V
MV
Kiseleva
T N
TN
Kazarian
E E
EE
Gurova
I V
IV
Smirnova
T V
TV
Shchegoleva
I V
IV
Loshchenov
V B
VB
Shevchik
S A
SA
Kuz'min
S G
SG
Vorozhtsov
G N
GN
D000368:Aged; D004596:Electroretinography; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008268:Macular Degeneration / Q000150:complications* / Q000175:diagnosis; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010778:Photochemotherapy / Q000379:methods*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012160:Retina / Q000473:pathology / Q000503:physiopathology; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D007211:Indoles; D009942:Organometallic Compounds; D011838:Radiation-Sensitizing Agents; C048577:aluminum tetrasulfophthalocyanine